



MEDICAMEN Organics Limited

Regd. & Corporate Office: 10, Community Centre No.2, Ashok Vihar Phase-II, Delhi-110052 (India)

Tel: 011-27430249, 27138171

E-mail: info@mediorganics.in | CIN No: L74899DL1995PLC066416 | GSTIN:07AABCM4302P1ZF

March 18, 2025

To,
National Stock Exchange of India Limited
Listing & Compliance Department
Exchange Plaza, 5th Floor, Plot No. C/1,
G Block, Bandra-Kurla Complex, Bandra
Mumbai - 400051 India.

Company Symbol : **MEDIORG**
Company ISIN : **INE0PE401018**

Dear Sir/Madam,

Subject: Press Release - Medicamen Organics Makes Preferential Allotment of Convertible Warrants to Promoter

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a copy of the Press Release titled - **“Medicamen Organics Makes Preferential Allotment of Convertible Warrants to Promoter”**.

A copy of the same will also be uploaded on the Company's website www.medicamenorganics.com.

Kindly take the same on record and display the same on the website of your exchange.

Thanking you.

Yours faithfully,

For and on behalf of
Medicamen Organics Limited

Ashutosh Gupta
Whole-time Director
DIN: 00039995

Place: New Delhi

Encl.: as stated above

Works:

Unit-1 : Plot No. 60, Sector 6-A, I.I.E. SIDCUL, Haridwar- 249403 (U.K.) | **GSTIN:** 05AABCM4302P1ZJ

Unit-2 : Plot No. 61, Sector 6-A, I.I.E. SIDCUL, Haridwar- 249403 (U.K.) | **GSTIN:** 05AABCM4302P3ZH



Medicamen Organics Makes Preferential Allotment of Convertible Warrants to Promoter

New Delhi, March 18, 2025 – Medicamen Organics Limited (MOL) (NSE- MEDIORG), is pleased to announce the successful allotment of 4,65,910 fully convertible warrants on a preferential basis to Mr. Bal Kishan Gupta, a promoter of the Company. Each warrant is issued at ₹64.39 and will be convertible into an equivalent number of equity shares of ₹10 each within 18 months from the date of allotment. The payment structure requires 25% of the warrant price to be paid at the time of allotment, with the remaining 75% payable upon conversion.

This strategic fund infusion underscores the promoter's confidence in the Company's future growth prospects. The capital raised through this preferential allotment will serve as a key enabler in achieving Medicamen Organics' expansion objectives and strengthening its market position.

Commenting on the development, Mr. Bal Kishan Gupta, Managing Director said, " "The pharmaceutical industry continues to grow steadily, and this capital infusion will enable us to leverage emerging opportunities while ensuring financial prudence. As a promoter, I remain highly confident in Medicamen Organics' future prospects. With this financial backing, we are committed to enhancing our competitive edge and delivering high-quality pharmaceutical solutions to the market. The Company remains focused on strategic growth, operational efficiency, and value creation for its stakeholders."

About Medicamen Organics Limited

Medicamen Organics Limited stands out as a prominent player in the pharmaceutical sector, specializing in the development, manufacturing, and distribution of an extensive range of pharmaceutical dosage forms. These include Tablets, Capsules, Oral Liquids, Ointments, Gels, Syrups, Suspensions, and Dry Powders. The company's diverse offerings serve both state and central government institutions as well as private entities, operating as a contract and third-party manufacturer.

The company has two WHO GMP-approved manufacturing facilities located in Haridwar, Uttarakhand, covering an area of 21,536 sq. ft. These facilities feature cutting-edge infrastructure and in-house testing laboratories. A team of skilled and experienced professionals supports a streamlined production process, maintaining consistent quality.

Focused on global expansion, the company's products are distributed not only throughout India but also in African, CIS, and Southeast Asian countries, including Congo, Benin, Cameg, Togo, Senegal, Burkina Faso, the Philippines, Myanmar, Mozambique, Kyrgyzstan, and Kenya.

The company's core business model revolves around B2B contract manufacturing, partnering with third-party pharmaceutical companies to market and sell its products. Medicamen Organics also engages actively in government tenders, supplying products to government hospitals, departments, PSUs, and armed forces.

The Company got listed on NSE Emerge in June 28, 2024.

For FY24, the Company has reported Total Income of ₹ 25.29 Cr, with EBITDA of ₹ 4.76 Cr & PAT of ₹ 2.62 Cr.

Disclaimer

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

For Further Information Please Contact Corporate Communication Advisor



Kirin Advisors Private Limited

Sunil Mudgal – Director

sunil@kirinadvisors.com

+91 98692 75849

www.kirinadvisors.com